Skip to main content
PRME
NASDAQ Life Sciences

Prime Medicine's Q3 10-Q Flags Going Concern Despite $134.7M Raise and 2027 Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.89
Mkt Cap
$705.556M
52W Low
$2.67
52W High
$5.91
52W Position info
46% above low
Off High info
34% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

PRME sits 46% above its 52-week low of $2.67.

Summary

Prime Medicine's Q3 10-Q shows a narrower $39.0 million net loss and $61.2 million of cash at September 30, yet management formally concludes substantial doubt about going concern for the next 12 months, even after the $134.7 million November offering that it says funds operations through 2027.


Key Events · Earnings and Guidance · PRME

  • Going Concern Doubt Formalized

    Management concluded substantial doubt exists about the company's ability to continue as a going concern for 12 months from the filing date, because the equity financing needed to fund operations is outside its control and cannot be counted as a mitigating factor under ASC 205-40.

  • Q3 Loss Narrows to $39.0M

    Net loss was $39.0 million ($0.22 per share) versus $50.6 million a year earlier; loss from operations was $39.9 million as R&D fell to $34.1 million from $44.0 million and G&A to $10.0 million from $11.2 million.

  • Cash of $61.2M at Quarter-End

    Cash, cash equivalents and short-term investments totaled $61.2 million at September 30, 2026, excluding $13.7 million of restricted cash, against an accumulated deficit of $1,018.6 million.

  • November Offering Nets $134.7M

    The company sold 41,071,428 shares at $3.50 per share, including the full 5,357,142-share greenshoe, for about $134.7 million net of $9.1 million in discounts and costs; management says this funds operations through 2027.


Analysis · PRME · Life Sciences

The quarter itself improved — net loss narrowed to $39.0 million from $50.6 million as R&D fell to $34.1 million from $44.0 million — but the formal going-concern conclusion is the headline. Management states substantial doubt exists about the company's ability to continue as a going concern for 12 months because the financing needed to fund operations sits outside its control and cannot be counted as a mitigating factor under ASC 205-40. In November, the company sold 41,071,428 shares at $3.50, raising about $134.7 million net, which it says funds operations through 2027; the going-concern language is an accounting conclusion tied to the September 30 cash balance of $61.2 million, not a statement that the raise failed. Investors are absorbing heavy dilution from the offering alongside a clinical calendar that includes initial PM577a and PM647 data in 2027 and a planned PM359 BLA in the first half of 2027.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRME was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $705.6M. The 52-week trading range was $2.67 to $5.91. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRME - Latest Insights

PRME
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.90
Real-time Price: $4.27 info
Change: +$0.370 (+9%) info
Market Cap: $774.479M info
PRME
Nov 12, 2026, 4:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.89
Real-time Price: $4.27 info
Change: +$0.380 (+10%) info
Market Cap: $774.479M info
PRME
Nov 10, 2026, 9:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $4.27 info
Change: +$0.5105 (+14%) info
Market Cap: $774.479M info
PRME
Nov 10, 2026, 4:43 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $4.27 info
Change: +$0.480 (+13%) info
Market Cap: $774.479M info
PRME
Nov 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $4.27 info
Change: +$0.470 (+12%) info
Market Cap: $774.479M info